Merck: agreement with China's Hansoh Pharma on GLP-1

(CercleFinance.com) - On Wednesday Merck announced the signature of a worldwide licensing agreement with Hansoh Pharma, with the aim of developing the experimental GLP-1 tablet developed by the Chinese pharmaceutical company.


With the signature of this agreement, Merck wants to strengthen its expertise in the field of incretin treatments, as well as study the potential of HS-10535, a small molecule designed for weight loss by Hansoh, on cardiometabolism.

In detail, Hansoh Pharma has granted Merck exclusive rights to develop, manufacture and market HS-10535 in return for an upfront payment of $112m.

Hansoh, which has reserved the rights for China, could receive a total of $1.9bn from Merck, depending on the project's progress, not including possible royalties on future product sales.


Copyright (c) 2024 CercleFinance.com. All rights reserved.